newsfilter
← Latest News
Business Wire·

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

On track for multiple Phase 2 data readouts with STAT3 inhibitor, TTI-101, with lead program in IPF expected in Q4 2025 Cash runway anticipated to be sufficient to fund operations into Q4 2026 Tvardi Therapeutics,